LT3725778T - Enzalutamido kompozicijos - Google Patents

Enzalutamido kompozicijos

Info

Publication number
LT3725778T
LT3725778T LTEP20177837.0T LT20177837T LT3725778T LT 3725778 T LT3725778 T LT 3725778T LT 20177837 T LT20177837 T LT 20177837T LT 3725778 T LT3725778 T LT 3725778T
Authority
LT
Lithuania
Prior art keywords
enzalutamide
formulations
Prior art date
Application number
LTEP20177837.0T
Other languages
English (en)
Lithuanian (lt)
Inventor
Douglas Alan Lorenz
Sanjay Konagurthu
Randy J. Wald
Jason A. Everett
Sheila Matz
Yuuki Takaishi
Toshiro Sakai
Ryousuke IRIE
Shinsuke Oba
Hiroyasu TOYOTA
Koji Nishimura
Atsushi Kanbayashi
Original Assignee
Medivation Prostate Therapeutics Llc
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49231627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3725778(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Llc, Astellas Pharma Inc. filed Critical Medivation Prostate Therapeutics Llc
Publication of LT3725778T publication Critical patent/LT3725778T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP20177837.0T 2012-09-11 2013-09-11 Enzalutamido kompozicijos LT3725778T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261699351P 2012-09-11 2012-09-11

Publications (1)

Publication Number Publication Date
LT3725778T true LT3725778T (lt) 2021-12-27

Family

ID=49231627

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP20177837.0T LT3725778T (lt) 2012-09-11 2013-09-11 Enzalutamido kompozicijos

Country Status (29)

Country Link
US (11) US20140179749A1 (OSRAM)
EP (6) EP3725778B1 (OSRAM)
JP (5) JP6404217B2 (OSRAM)
KR (1) KR102225416B1 (OSRAM)
CN (2) CN109897004A (OSRAM)
AU (2) AU2013315619B2 (OSRAM)
BR (1) BR112015005432B1 (OSRAM)
CA (1) CA2884795C (OSRAM)
CY (1) CY1124729T1 (OSRAM)
DK (1) DK3725778T3 (OSRAM)
EA (2) EA033374B9 (OSRAM)
ES (1) ES2892029T3 (OSRAM)
HK (1) HK1212701A1 (OSRAM)
HR (1) HRP20211423T1 (OSRAM)
HU (1) HUE057701T2 (OSRAM)
IL (1) IL237604B (OSRAM)
IN (1) IN2015DN02875A (OSRAM)
LT (1) LT3725778T (OSRAM)
MX (3) MX363974B (OSRAM)
PH (1) PH12015500525A1 (OSRAM)
PL (1) PL3725778T3 (OSRAM)
PT (1) PT3725778T (OSRAM)
RS (1) RS62676B1 (OSRAM)
SI (1) SI3725778T1 (OSRAM)
SM (1) SMT202100550T1 (OSRAM)
TW (1) TWI673051B (OSRAM)
UA (1) UA117353C2 (OSRAM)
WO (1) WO2014043208A1 (OSRAM)
ZA (1) ZA201501847B (OSRAM)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033374B9 (ru) 2012-09-11 2019-12-18 Медивейшн Простейт Терапьютикс Ллк Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
UA115805C2 (uk) * 2013-04-17 2017-12-26 Сігнал Фармасьютікалз, Елелсі Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати
CN112402360A (zh) * 2014-02-05 2021-02-26 斯洛文尼亚莱柯制药股份有限公司 雄激素受体拮抗剂的固体药物组合物
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
MA41111B1 (fr) 2014-12-05 2021-09-30 Aragon Pharmaceuticals Inc Compositions anticancéreuses
RS66323B1 (sr) * 2014-12-05 2025-01-31 Aragon Pharmaceuticals Inc Sastavi protiv raka
CN106999430A (zh) * 2014-12-05 2017-08-01 阿拉贡药品公司 抗癌组合物
EP3256495A4 (en) * 2015-02-11 2018-09-19 Aptevo Research and Development LLC Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
CN104546714A (zh) * 2015-02-11 2015-04-29 江苏慧博生物科技有限公司 一种恩杂鲁胺胶束制剂及其制备方法
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN105030685B (zh) * 2015-07-21 2018-02-27 福格森（武汉）生物科技股份有限公司 一种恩杂鲁胺固体分散体口服制剂
US20180235935A1 (en) 2015-08-12 2018-08-23 Medivation Prostate Therapeutics Llc Treatment of Cancer with Enzalutamide and a CYP3A4 Inhibitor
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
WO2018015958A1 (en) 2016-07-21 2018-01-25 Hadasit Medical Research Services And Development Ltd. Ar antagonists or inhibitors for use in treating glioblastoma
CA3036011A1 (en) 2016-08-20 2018-03-01 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
ES2886842T3 (es) * 2017-04-13 2021-12-21 Jean Paul Remon Composiciones a base de xanthohumol
US12036315B2 (en) 2017-04-28 2024-07-16 Astellas Pharma Inc. Pharmaceutical composition for oral administration comprising enzalutamide
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
WO2019016747A1 (en) * 2017-07-20 2019-01-24 Dr. Reddy's Laboratories Limited AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION
BR112020002705A2 (pt) * 2017-08-08 2020-07-28 Dr. Reddys Laboratories Limited composições extrudadas de enzalutamida
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
US20200397756A1 (en) * 2018-02-09 2020-12-24 Kashiv Biosciences, Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
ES2967689T3 (es) 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
EP3873443A4 (en) 2018-10-30 2022-07-27 Peloton Therapeutics, Inc. SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS WITH A SUBSTITUTED INDAN AND PROCESSES FOR THEIR PREPARATION AND USE THEREOF
EA202191372A1 (ru) * 2018-12-14 2021-09-16 Фуджифилм Корпорэйшн Таблетка и способ получения таблетки
CN109432016B (zh) * 2018-12-26 2021-03-02 广州中医药大学(广州中医药研究院) 一种恩杂鲁胺的三元固体制剂及其制备方法
WO2020144647A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Pharmaceutical composition comprising apalutamide dispersed in apple sauce
US20210115517A1 (en) 2019-01-30 2021-04-22 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
JP2022523094A (ja) 2019-01-30 2022-04-21 アラゴン ファーマシューティカルズ，インコーポレイテッド 転移性去勢感受性前立腺癌の治療のための抗アンドロゲン剤
US20220133638A1 (en) 2019-05-16 2022-05-05 Leon-Nanodrugs Gmbh Method for producing nanoparticles
EP3972569A1 (en) 2019-05-23 2022-03-30 Helm AG Nanoparticles comprising enzalutamide
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
EP3990435A1 (en) 2019-06-27 2022-05-04 Synthon B.V. Process for preparation of enzalutamide
CN119424435A (zh) * 2019-09-18 2025-02-14 百时美施贵宝公司 Tyk2抑制剂的剂型
CN118319863A (zh) * 2019-09-23 2024-07-12 生态有限公司 治疗制剂及其用途
CA3152909A1 (en) 2019-10-03 2021-04-08 Synthon Bv Pharmaceutical composition comprising enzalutamide
CA3160121A1 (en) 2019-11-04 2021-05-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
EP4146170A1 (en) * 2020-05-06 2023-03-15 Disruptive Pharma AB Novel amorphous active pharmaceutical ingredients
AR118925A1 (es) * 2020-05-13 2021-11-10 Novocap S A Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
CN114053243B (zh) * 2020-08-05 2024-11-12 齐鲁制药有限公司 一种恩扎卢胺软胶囊及其制备方法
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
SMT202500315T1 (it) * 2020-09-09 2025-11-10 Crinetics Pharmaceuticals Inc Formulazioni di un modulatore della somatostatina
IL301389A (en) * 2020-09-18 2023-05-01 Bristol Myers Squibb Co Dosage forms for tyk2 inhibitors comprising swellable cores
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
MX2023012597A (es) 2021-07-07 2023-12-07 Bdr Pharmaceuticals Intl Pvt Ltd Nuevas composiciones liquidas orales de enzalutamida y metodo de fabricacion de las mismas.
CN115721612B (zh) * 2021-08-26 2024-07-26 上海宣泰医药科技股份有限公司 一种恩扎卢胺固体制剂颗粒及其制备方法
CN118251213A (zh) * 2022-01-19 2024-06-25 四川科伦药物研究院有限公司 固体分散体及其制备方法和包含其的药物组合物
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
CN114224832A (zh) * 2022-02-11 2022-03-25 明度智云(浙江)科技有限公司 一种恩杂鲁胺注射剂及其制备方法和应用
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
WO2023244617A1 (en) * 2022-06-13 2023-12-21 Virginia Polytechnic Institute And State University Amphiphilic cellulose derivatives, methods of making, and uses thereof
TW202416960A (zh) * 2022-06-17 2024-05-01 美商特朗奎斯治療股份有限公司 2-芳基苯并咪唑化合物之調配物
CN115887395A (zh) * 2022-11-18 2023-04-04 上海药坦药物研究开发有限公司 恩杂鲁胺固体分散体制剂及其制备方法和应用
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
WO2024153733A1 (en) 2023-01-18 2024-07-25 Helm Ag Crystalline nanoparticles comprising enzalutamide
WO2024191660A2 (en) * 2023-03-10 2024-09-19 Yale University Compositions and methods for treating steroid hormone-related diseases or disorders
AU2024236119A1 (en) 2023-03-16 2025-09-25 Bayer Consumer Care Ag Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer
WO2025052925A1 (ja) * 2023-09-08 2025-03-13 沢井製薬株式会社 エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法
KR20250058470A (ko) 2023-10-23 2025-04-30 케이원팜 주식회사 안정성과 용출특성이 향상된 신규 엔잘루타마이드 함유 조성물 및 이의 제조방법
EP4520322A1 (en) * 2023-12-06 2025-03-12 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical compositions containing enzalutamide
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide
KR20250100928A (ko) 2023-12-27 2025-07-04 케이원팜 주식회사 생체이용률이 개선된 엔잘루타마이드 약학 조성물 및 이의 제조방법
CN118001243B (zh) * 2024-01-31 2024-10-22 四川鲁徽制药有限责任公司 一种恩杂鲁胺口腔崩解片及其制备方法
TR2024004340A1 (tr) * 2024-04-05 2025-10-21 Abdi̇ İbrahi̇m İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Enzalutamidin katı dispersiyonu.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
EP1745774A3 (en) 1997-08-11 2007-04-11 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
IN191496B (OSRAM) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
AR027656A1 (es) 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
JP3548566B2 (ja) 2001-02-27 2004-07-28 アストラゼネカ アクチボラグ 医薬製剤
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
SE0103839D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
BR0307515A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
EP1499662A1 (en) 2002-04-18 2005-01-26 Avecia Limited Prepation of a conjugated molecule and materials for use therein
JP4249950B2 (ja) 2002-06-28 2009-04-08 富士フイルム株式会社 紙管切断装置及び紙管切断方法
WO2004074350A2 (en) 2003-02-21 2004-09-02 Hetero Drugs Limited Bicalutamide polymorphs
US7611630B2 (en) 2004-03-30 2009-11-03 Bend Research, Inc. Method and device for evaluation of pharmaceutical compositions
KR101332889B1 (ko) * 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP1885338A1 (en) 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
JP2009502969A (ja) 2005-07-28 2009-01-29 アイエスピー インヴェストメンツ インコーポレイテッド 非晶質エファビレンツ及びその製造
EP4385574A3 (en) 2006-03-27 2024-10-02 The Regents of the University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US20100151035A1 (en) 2007-03-13 2010-06-17 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
WO2009113522A1 (ja) * 2008-03-11 2009-09-17 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
ES2880354T3 (es) * 2010-02-24 2021-11-24 Medivation Prostate Therapeutics Llc Procesos para la síntesis de compuestos de diariltiohidantoína y diarilhidantoína
CN103118681B (zh) * 2010-03-10 2015-02-18 艾伯维巴哈马有限公司 固体组合物
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
CN113135892A (zh) 2012-06-07 2021-07-20 阿拉贡药品公司 雄激素受体调节剂的晶形
EP2883271B1 (en) * 2012-08-10 2020-07-22 Keyssa, Inc. Dielectric coupling systems for ehf communications
EA033374B9 (ru) 2012-09-11 2019-12-18 Медивейшн Простейт Терапьютикс Ллк Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
JP2015534550A (ja) 2012-09-11 2015-12-03 ドクター レディズ ラボラトリーズ リミテッド エンザルタミドの多形形態およびその調製
WO2014042945A1 (en) 2012-09-11 2014-03-20 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
US12036315B2 (en) 2017-04-28 2024-07-16 Astellas Pharma Inc. Pharmaceutical composition for oral administration comprising enzalutamide
US20190208236A1 (en) 2018-01-02 2019-07-04 Source Digital, Inc. Coordinates as ancillary data
CA3152909A1 (en) 2019-10-03 2021-04-08 Synthon Bv Pharmaceutical composition comprising enzalutamide

Also Published As

Publication number Publication date
IL237604A0 (en) 2015-04-30
PH12015500525A1 (en) 2015-05-04
CN105358535A (zh) 2016-02-24
WO2014043208A1 (en) 2014-03-20
TW201427659A (zh) 2014-07-16
BR112015005432A2 (OSRAM) 2017-09-05
US11839689B2 (en) 2023-12-12
SI3725778T1 (sl) 2022-02-28
TWI673051B (zh) 2019-10-01
AU2018200316A1 (en) 2018-02-08
EP4324527A2 (en) 2024-02-21
US20170224624A1 (en) 2017-08-10
US12502357B2 (en) 2025-12-23
US20250049721A1 (en) 2025-02-13
HUE057701T2 (hu) 2022-05-28
JP2018087206A (ja) 2018-06-07
MX363974B (es) 2019-04-10
JP6404217B2 (ja) 2018-10-10
EA033374B9 (ru) 2019-12-18
AU2013315619A1 (en) 2015-04-30
MX2021000007A (es) 2021-03-09
KR20150082203A (ko) 2015-07-15
UA117353C2 (uk) 2018-07-25
US20200060976A1 (en) 2020-02-27
EP4450130A3 (en) 2025-01-08
KR102225416B1 (ko) 2021-03-09
EA201500314A1 (ru) 2015-12-30
PL3725778T3 (pl) 2021-12-20
JP6932746B2 (ja) 2021-09-08
US20190209476A1 (en) 2019-07-11
JP2021178871A (ja) 2021-11-18
US12447128B2 (en) 2025-10-21
EP3971167A1 (en) 2022-03-23
RS62676B1 (sr) 2021-12-31
EA033374B1 (ru) 2019-10-31
JP2016204392A (ja) 2016-12-08
ES2892029T3 (es) 2022-02-01
CN105358535B (zh) 2019-01-04
EP2895463A1 (en) 2015-07-22
US20140100256A1 (en) 2014-04-10
ZA201501847B (en) 2016-01-27
MX2015003140A (es) 2015-12-16
EP3725778B1 (en) 2021-08-18
PT3725778T (pt) 2021-09-22
US20170027910A1 (en) 2017-02-02
JP2015527411A (ja) 2015-09-17
HRP20211423T1 (hr) 2022-01-21
EP4324527A3 (en) 2024-04-24
AU2013315619B2 (en) 2018-02-08
US20230122911A1 (en) 2023-04-20
US20230210778A1 (en) 2023-07-06
US20250090465A1 (en) 2025-03-20
EA201991484A1 (ru) 2019-11-29
IL237604B (en) 2021-07-29
CN109897004A (zh) 2019-06-18
CY1124729T1 (el) 2022-07-22
IN2015DN02875A (OSRAM) 2015-09-11
DK3725778T3 (da) 2021-09-20
JP2019194262A (ja) 2019-11-07
SMT202100550T1 (it) 2022-01-10
US20140378517A1 (en) 2014-12-25
EP4450130A2 (en) 2024-10-23
BR112015005432B1 (pt) 2023-04-18
CA2884795A1 (en) 2014-03-20
EP3725778A1 (en) 2020-10-21
EP4169908A1 (en) 2023-04-26
US20140179749A1 (en) 2014-06-26
CA2884795C (en) 2023-10-17
MX2019003984A (es) 2019-08-12
HK1212701A1 (zh) 2016-06-17

Similar Documents

Publication Publication Date Title
ZA201501847B (en) Formulations of enzalutamide
PL2877155T3 (pl) Formulacje opioidowe
ZA201407373B (en) Novel pharmaceutical formulations
SG10201912291YA (en) Vaccine compositions
SI2827862T1 (sl) Formulacije bendamustina
IL289157A (en) Opioid compounds
ZA201406082B (en) Use of ccr3-inhibitors
ES3050125T3 (en) Bromocriptine formulations
ZA201306000B (en) Stable formulation
SG11201504134SA (en) External preparation
GB201501016D0 (en) Preparation of 18F-fluciclovine
GB201312378D0 (en) Structure of shoe
IL217807A0 (en) Therapeutic compositions
GB201210530D0 (en) Extended release formulations
ZA201502350B (en) Solid form of hihydro-pyrido-oxazine derivative
PL2908859T3 (pl) Formulacje arypiprazolu
GB201206178D0 (en) Formulations
IL233879A0 (en) Dry powdered dnase i preparations
TWM433525U (en) Structure of calorifier
SI2928896T1 (sl) Trdna oblika derivata dihidro-pirido-oksazina
GB201211247D0 (en) Improved formulation
GB201216165D0 (en) Virtues iBrush
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations